Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:866-873

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bouchie, J. L.
Right arrow Articles by Feener, E. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bouchie, J. L.
Right arrow Articles by Feener, E. P.
Related Collections
Right arrow Fibrinolysis
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:866.)
© 2000 American Heart Association, Inc.


Thrombosis

P2Y Receptor Regulation of PAI-1 Expression in Vascular Smooth Muscle Cells

Julie L. Bouchie; Hong-Chi Chen; Rebbeca Carney; J. Courtney Bagot; Peter A. Wilden; Edward P. Feener

From the Research Division, Joslin Diabetes Center, Harvard Medical School, Boston, Mass (J.L.B., H.-C.C., R.C., E.P.F.), and the Department of Pharmacology and Molecular Biology Program, University of Missouri, School of Medicine, Columbia, Mo (J.C.B., P.A.W.).

Correspondence to Edward P. Feener, PhD, Research Division, Joslin Diabetes Center, One Joslin Place, Boston, MA 02215. E-mail edward.feener{at}joslin.harvard.edu

Abstract—P2Y-type purine and pyrimidine nucleotide receptors play important roles in the regulation of vascular hemostasis. In this article, the regulation of plasminogen activator inhibitor-1 (PAI-1) expression in rat aortic smooth muscle cells (RASMCs) by adenine and uridine nucleotides was examined and compared. Northern analysis revealed that RASMCs express multiple P2Y receptor subtypes, including P2Y1, P2Y2, and P2Y6. Treatment of RASMCs with UTP increased PAI-1 mRNA expression and extracellular PAI-1 protein levels by 21-fold (P<0.001) and 7-fold (P<0.001), respectively. The ED50 for the effect of UTP on PAI-1 expression was {approx}1 µmol/L, and its maximal effect occurred at 3 hours. UDP stimulated a 5-fold increase (P<0.005) in PAI-1 expression. In contrast to these potent stimulatory effects of uridine nucleotides, ATP and 2-methylthioadenosine triphosphate (2-MeSATP) caused a small and transient increase in PAI-1 mRNA at 1 hour, followed by a rapid decrease to baseline levels. ADP produced only an inhibitory effect, reducing PAI-1 mRNA levels by 63% (P<0.05) at 3 hours. The relative nucleotide potency in stimulating PAI-1 expression is UTP>UDP>ATP=2-MeSATP, consistent with a predominant role of the P2Y6 receptor. Further studies revealed that exposure of RASMCs to either ATP or ADP for 3 hours inhibited both UTP- and angiotensin II–stimulated PAI-1 expression by up to 90% (P<0.001). Thus, ATP induced a small and transient upregulation of PAI-1 that was followed by a strong inhibition of PAI-1 expression. These results show that extracellular adenine and uridine nucleotides exert potent and opposing effects on vascular PAI-1 expression.


Key Words: purinoceptors • nucleotides • plasminogen activator inhibitor • vascular smooth muscle cells • rats




This article has been cited by other articles:


Home page
DiabetesHome page
D. J. Friedman, H. G. Rennke, E. Csizmadia, K. Enjyoji, and S. C. Robson
The Vascular Ectonucleotidase ENTPD1 Is a Novel Renoprotective Factor in Diabetic Nephropathy
Diabetes, September 1, 2007; 56(9): 2371 - 2379.
[Abstract] [Full Text] [PDF]